Summary.-The results of radiation therapy in 212 patients with stages I and II Hodgkin's disease treated between 1963 and 1973 show that approximately 60% remain disease-free following treatment. Multiple node involvement in stage II, particularly associated with infraclavicular node disease, is identified as a group where the relapse rate is high. This presentation is associated particularly with NS.
In a group of 78 patients treated with radiotherapy following staging laparotomy and splenectomy approximately 80% remain in complete remission. The preliminary results of treatment in PS IIIa patients are substantially the same as those for PS I and II; the results of treatment for NS and MC disease are similar. The significance of involvement of the spleen is discussed. Although it is probable that Hodgkin's disease spreads to the spleen through the blood stream it is suggested that splenic involvement does not necessarily indicate that the involvement of other extralymphatic structures such as liver and marrow has occurred. However, when the nodes in the porta hepatis are involved splenic Hodgkin's disease may well be associated with an increased risk of occult hepatic infiltration.
HODGKIN'S disease, untreated or inadequately treated, carries a grave prognosis. However, important advances in the investigation and treatment of this condition have occurred over the past [10] [11] [12] [13] [14] [15] years and the major issues of pathological classification and clinical and pathological staging (Carbone et al., 1972 )* have been discussed and clarified at several international meetings held during this period (Paris, 1966; Rye, 1966; Stanford, 1973) .
Results of previous treatment in this hospital have been reported in several publications (Smithers, 1969; Smithers and Peckham, 1973; Peckham, 1973 b) . Experience in the biology, investigation and management of Hodgkin's disease at the Royal Marsden Hospital and Stanford University has been presented separately in monographs published in 1973 (Kaplan, 1972; Smithers, 1973) .
Laparotomy and splenectomy was first employed at this centre in 1969 and experience has amply demonstrated that failure of treatment based upon a purely clinical assessment of the extent of disease may be due in large part to the presence of undetected occult abdominal tumour, particularly involvement of the spleen (Glatstein et al., 1969; Gazet, 1973) .
The current radiotherapeutic management of Hodgkin's disease has developed from the concepts described by Gilbert (1939) and developed by Peters (1950) . An important feature of this approach is the concept of treating apparently uninvolved nodal areas adjacent to clinically obvious disease. The present form of treatment was developed by Kaplan (1962) who demonstrated that irradiation of the axial lymphatic system (total nodal irradiation) was a practical procedure (Kaplan and Rosenberg, 1966 ). An alternative approach to therapy has been advocated by Johnson et al. (1970) Treatment methods.-These have been described in a previous publication (Peckham, 1973b) and will be mentioned only briefly. Between 1963 and 1969 patients with supradiaphragmatic stage I and II disease received irradiation by the mantle technique which involves the en-bloc irradiation of the mediastinal, axillary and cervical nodal areas using large anterior and posterior fields, the majority of patients being treated with a linear accelerator. During this time, CS Illa patients who did not have splenic enlargement either clinically or on scanning and in whom systemic symptoms were absent received total nodal irradiation in which the mantle treatment was followed after an interval of one month by irradiation of the para-aortic, iliac and inguinal nodes (inverted " Y " field). The spleen was not irradiated or removed in this group of patients. Patients with infradiaphragmatic stage I and II disease were treated with the inverted " Y " technique. After the introduction of laparotomy, PS I and II patients with supradiaphragmatic disease were treated initially with a mantle field but when it became evident that a small proportion were relapsing in the para-aortic region, even when both lymphogram and laparotomy were negative, it was decided to irradiate this region. This is done with a separate field extending down to L5/S1 interspace and treatment is started about one month after completion of supradiaphragmatic irradiation. PS Illa patients receive total nodal irradiation which includes the splenic axis if the spleen was involved by tumour.
The survival rates were computed by the actuarial method incorporating a correction for expected deaths due to causes other than Hodgkin's disease. The correction was made using national mortality statistics by the method of Berkson and Gage (1950) .
Patients. The time interval between treatment and relapse in stages I and II patients is shown in Fig. 1 . 54% of relapses occurred within 12 months and 85% within 24 months of radiation therapy with few occurring after 36 months. In 68% of patients with loco-marginal recurrence this became apparent within 12 months of treatment. There is a suggestion, as might be expected, that local relapse appears sooner than abdominal relapse. Fig. 2 summarizes the diseasefree rates in stages I and II disease in histogram form and shows that in those patients with multiple nodal areas involved (Ila(3+)) the relapse rate is high.
Fortunately, the most common presentation within stage II is associated with involvement of 2 or 3 nodal areas. Fig. 3 shows the disease-free survival of stages I and II patients isolating those patients with more than 3 nodal areas involved. This group is frequently associated with infraclavicular disease and 
DISCUSSION
The rapid evolution which has occurred in the management of Hodgkin's disease as a result of the introduction of several important investigative and therapeutic techniques has rendered an appraisal of treatment results difficult, especially since most of these changes have occurred within the short space of one decade. The majority of clinical trials which have been undertaken were carried out before the advent of staging laparotomy. This latter procedure has clearly demonstrated that splenic involvement may be present in patients with apparently localized supradiaphragmatic disease. The proportion of positive spleens will clearly depend upon patient selection, in particular upon the distribution of patients according to histological subtype. In our own series approximately 40% of patients submitted to laparotomy have histological evidence of involvement of the spleen. From the outset it has been our policy to treat one group of patients with radiation therapy alone (stages I, II and Illa) and another group, with more advanced disease, with combination chemotherapy (stages IIIb and IV). By adopting this policy it was hoped that bad-risk groups could be identified as suitable for treatment with both irradiation and chemotherapy, while at the time same avoiding the overtreatment of the majority of patients. As reported in a previous publication (Peckham, 1973b ) about 60% of CS I and II patients remain disease-free after radiation therapy and since relapse has generally occurred within 3 years of therapy, it is reasonable to suppose that a substantial proportion of this group may be considered as cured of their disease. The time to relapse after irradiation in the present series shows that in 85% of patients who relapse this has occurred by 2 years. This is similar to the figure of 82% reported by the Stanford group (Spittle et al., 1973 CS I presentations with MC disease who have undergone laparotomy in the past 3 years in this hospital, no less than 11 have had involved spleens and if the fate of those patients who were treated in the prelaparotomy period and who presented in a similar way is examined it is not surprising to find that only 1 of 7 patients remains disease-free, with 6 relapses occurring in the abdominal cavity. Thus, in the era when clinical staging alone was employed (1963-69) we would expect to see an important difference between the treatment results in the different histological subgroups. Certainly LD is associated with an appalling prognosis with 8 of 10 patients (stages I, II and Illa) having died of Hodgkin's disease. The difference in disease-free survival rate between LP and MC is marked but there is little difference between NS and MC. These results suggests that factors other than undetected, and hence untreated, abdominal disease may have influenced the treatment results. It is apparent that patients with multiple nodal involvement above the diaphragm have proved difficult to control with radiotherapy and if the group with more than 3 nodal areas involved is considered alone, the diseasefree and overall survival results are seen to be markedly inferior to the stages I and II results as a whole. This is particularly true of NS, where more than 90% of patients in this small group have relapsed. These patients often have infraclavicular node involvement and, as Table V shows, when this is present the chances of relapse are high. In this group an association of chemotherapy with radiotherapy is indicated and we now prefer to precede irradiation by several courses of combination chemotherapy, continued until the patient is in complete remission.
It may be argued that the improvement in treatment results for radiotherapy in PS patients may be due to the reallocation of the more advanced patients to the chemotherapy group (PS IIlb and IV) following laparotomy. In our experience liver involvement in CS I, II and Illa is rare and the transition of patients from these stage categories to stage IV has been exceptionally uncommon. CS lb and Ilb patients who prove to have abdominal disease and who are placed in the PS IIlb group would have been treated with chemotherapy rather than irradiation. In fact, this occurred in only 6 patients.
The important question as to whether therapy based upon the findings of PS procedures is likely to improve treatment results depends in large part on whether involvement of the spleen indicates widespread haematogenous dissemination or whether Hodgkin's disease of the spleen still represents tumour localized to the lymphatic system. The mechanism whereby Hodgkin's disease spreads to the spleen is unknown. Halie et al. (1972) have described the presence of large circulating cells of indeterminate type in patients with splenic involvement and suggested that Hodgkin's disease spreads to the spleen via the blood stream and that splenic involvement is an indicator of disseminated disease. Quantitative cytochemical studies carried out in one of our patients at presentation and subsequently in relapse when splenic involvement was diagnosed, showed a narrower range of nuclear DNA contents in splenic Hodgkin's tissue (comparable with the initial biopsy) compared with the marked aneuploidy of the para-aortic node removed at the same time as the spleen (Peckham, 1973a) . This observation is consistent with the hypothesis that foci of Hodgkin's disease in the spleen are established by cells circulating from the large mass of nodal tumour. The question perhaps is not so much whether Hodgkin's disease spreads to the spleen via the blood stream but whether this necessarily indicates metastases to other extralymphatic sites, particularly the liver and the marrow. That "organ-localized" haematogenous spread can occur in malignant disease is demonstrated by the cure occasionally effected in testicular teratoma by the excision of solitary pulmonary metastases and in colonic carcinoma by p)artial hepatectomy for liver metastases.
Ln a recent study of the fate of circulating lymphoma cells in the murine Hodgkinlike type-B neoplasm, Parks (1974) has shown that initial uptake of iododeoxuridine labelled tumour cells in the lung, liver, kidney and spleen was followed by progressive depletion of tumour cells in all sites except the spleen, which at autopsy proved to be the only site where tumour nodules could be demonstrated.
It has been suggested that involvement of the spleen in Hodgkin's disease is strongly correlated with hepatic infiltration and that some form of systemic therapy is therefore indicated in patients with splenic Hodgkin's disease (Kaplan, 1970) . On this basis, patients in the Stanford trials have received either chemotherapy in addition to total nodal irradiation or intravenous radioactive colloidal gold and hepatic irradiation (Kraut, Kaplan and Bagshaw, 1972; Rosenberg et al., 1972) . On the other hand, the results reported by Johnson et al. (1970) who have irradiated the spleen electively in CS I and II, where it might be expected that at least one-third of patients would have had splenic Hodgkin's disease, are consistent with the conclusion that splenic Hodgkin's disease is locally curable and not therefore invariably associated with hepatic involvement. On the basis of a preliminary report, Shipley, Piro and Hellman (1974) On the basis of our own observations and those described above, it is suggested that although spread to the spleen via the blood stream may occur, such spread may be localized to the spleen where it is curable by localized forms of therapy such as irradiation or surgery.
It is clearly premature to be able to sustain this hypothesis with clinical evidence and our preliminary information suggests that the presence of porta hepatis node involvement in association with involvement of the spleen might well indicate occult, undetected hepatic Hodgkin's disease. If, as seems likely, radical radiotherapy based upon the accurate disease localization, provided by clinical and pathological staging techniques does prove to be an advance upon previous treatment methods, then we might expect staging and perhaps also histological grade to become less important prognostic indicators. The results shown in Fig. 4 suggest that this is occurring in that the disease-free survival of patients has been enhanced considerably by PS with the results for stage Illa patients being substantially the same as those for stages I and II.
